Open SurgeryPRECISENCT06725030
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
An observational study of Open Surgery and Lymphedema, run by MMI (Medical Microinstruments, Inc.) at 8 sites in United States.
Trial summary
The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery. The primary endpoints are: Effectiveness- Rate of intraoperative anastomosis patency at first attempt. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Open Surgery, Lymphedema, Free Tissue Transfer
- What is being tested?
- Symani Surgical System
- Type of treatment
- Medical device
- How many people
- 455 participants
- Where
- 8 sitesUnited States
- Study dates
- 22 Sep 2025to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patients selected for the PRECISE Study will be adults with a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities.
Pre Operative Inclusion Criteria:
- At least 22 years of age
- Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure
- Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free-flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities
- Investigator deems the candidate acceptable for free flap transfer surgery and/or lymphovenous anastomosis surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)
Cohort Specific Pre- Operative Inclusion Criteria:
Free Tissue Transfer Surgery: N/A
Lymphovenous Anastomosis Surgery
- Swelling of one limb that is not completely reversed by elevation or compression
- Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system
- At least one of the following positive quantitative measurements:
- Volumetry differential between affected limb and contralateral limb must be at least 10% of the other
- Bioimpedance (L-Dex) differential, if feasible, between affected limb and contralateral limb of at least 10 units
- Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines, for at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen
- Willingness to comply with recommended regimen of self-care, with consistent use of appropriately sized compression garments from screening through the entire study duration (through the 3-month follow-up visit).
Pre-Operative Exclusion Criteria:
- Patients who are incapable and/or unwilling to provide informed consent
- Active systemic infection under treatment with intravenous antibiotics
- Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion
- Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
- Patients with implanted pacemaker
- Planned vein graft
- Currently receiving chemotherapy or radiation therapy
- History of chronic kidney disease
- History of chronic liver disease
- Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes
- Patients belonging to vulnerable populations, such as pregnant women, or ineligible to participate for other reasons in the judgement of the investigator
Cohort Specific Pre-Operative Exclusion Criteria:
Free Tissue Transplant Surgery:
- Patients with buried flaps
- Multiple flaps planned for the procedure
Lymphovenous Anastomosis Surgery:
- Patients > 75 years of age
- Patients with prior lymphatic reconstruction surgery
- Patients with venous edema (arising from increased capillary filtration)
- Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure
- Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema
- Current infection in the affected limb
- Patients who experience more than one episode of cellulitis in a six month period over the past two years
- Current evidence or a history of malignancy within the past 6 months (if the participant has undergone cancer treatment, this must have been completed > 6 months prior to enrollment)
- Known iodine sensitivity
- Patient's lymphatic disease is due to lipedema
- Patients with bilateral lymphedema or lymphedema in multiple anatomical locations
Intra Operative Exclusion Criteria:
- Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest
- The patient does not have at least one robotic stitch attempted during the index procedure
Trial locations and contacts
8 sites in 1 country. Contact the study team or a site near you to ask about taking part.
8 sites in 1 country
United States8 sites, 8 recruiting
- Recruiting
Cedars Sinai Medical Center
Beverly Hills, California, 90048
Laura Sarmiento, Laura.Sarmiento@cshs.org
Curtis Cetrulo
- Recruiting
Erie County Medical Center
Buffalo, New York, 14215
Sonja Williams, swilliam8@ecmc.edu
Mark Falco
- Recruiting
Cleveland Clinic
Cleveland, Ohio, 44195
Beverly Doyle, plasticsurgeryresearch@ccf.org
Graham Schwarz
- Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, 07601
Samuel Belony, samuel.belony@hmhn.org
Richard Winters
- Recruiting
Yale New Haven Hospital
New Haven, Connecticut, 06511
Kyra Jersey, kyra.jersey@yale.edu
Luccie Wo
- Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Emily Svendsen, Emily.Svendsen@mountsinai.org
Alice Yao
- Recruiting
HCA Healthcare Trident Hospital
North Charleston, South Carolina, 29406
Vera Markovic, vera.markovic@hcahealthcare.com
Joshua Hornig
- Recruiting
Tampa General Hospital
Tampa, Florida, 33606
Chloe Grabowski, cchapin@tgh.org
Nicholas Panetta
About this study
Official title: PRECISE: A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery.
The primary endpoints are:
Read more
- Effectiveness- Rate of intraoperative anastomosis patency at first attempt.
- Safety- Freedom from device-related adverse events.
Participants will receive treatment as standard of care and be asked to:
- Allow the researchers to access and use their information.
- If participants are undergoing a lymphedema procedure, they will be asked to undergo a questionnaire as part of the study.
- Participants will be asked to comply with the follow-up visits and complete all study procedures/questionnaires as outlined in the protocol.
- Being tested
- Symani Surgical System
- Medical subject headings
- Lymphedema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Symani Surgical SystemDevice
The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
| Study group | Role | What they receive |
|---|---|---|
| Free Tissue Transfer Surgery | Not described Receives: Device: Symani Surgical System | |
| Lymphovenous Anastomosis Surgery | Not described Receives: Device: Symani Surgical System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Freedom from device-related adverse events from the start of the index procedure through 30-days post index procedure as adjudicated by a Clinical Events Committee
All adverse events will be evaluated from the start of the index procedure through 30-days post index procedure. Adverse events will be reviewed by a Clinical Events Committee (CEC) to determine probable or causal relationships with the device. All device-related serious adverse events will be summarized descriptively.
Measured: From participants index procedure through 30-days post index procedure.
Intraoperative anastomosis patency at first attempt.
Intraoperative anastomosis patency will be measured for each robotic anastomosis per standard of care and will be evaluated after the first attempt of the anastomosis during the index procedure.
Measured: The duration of the participants index procedure.
Secondary outcomes (5)
Intraoperative anastomosis patency prior to closure.
Intraoperative anastomosis patency prior to closure will be measured for each robotic anastomosis per standard of care and will be evaluated prior to closure of the procedure site during the index procedure.
Measured: The duration of participants index procedure.
Anastomosis suturing time (including robotic time and manual time).
Anastomosis suturing time of the index procedure will be collected for each participant and summarized. Robotic anastomosis time and manual anastomosis time will be recorded for each anastomosis. For each anastomosis within an operation, the total suture time (robotic plus manual) will be derived as total robotic anastomosis time plus total manual anastomosis time.
Measured: The duration of participants index procedure.
Number of robotic and manual stitches per anastomosis.
The number of robotic stitches placed and the number of manual stitches placed per anastomosis in the index procedure will be collected for each anastomosis and summarized. For each anastomosis within an operation, the total stitches placed (robotic plus manual) will be derived as total robotic stitches placed plus total manual stitches.
Measured: The duration of participants index procedure.
Procedure time.
Procedure time of the index procedure will be collected for each participant and summarized. The incision start time and closure end time will be recorded. The procedural time will be derived from incision time subtracted from closure time.
Measured: The duration of participants index procedure.
Technical Success.
Technical success is defined as freedom from device malfunction resulting in unplanned conventional suturing. Device malfunctions and the associated outcome will be collected. This endpoint will be evaluated throughout the index procedure.
Measured: The duration of participants index procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2024
- Study start22 Sep 2025
- Primary completion1 Sep 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Open SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 455 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MMI (Medical Microinstruments, Inc.)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bohdan Pomahac, MD, Principal investigator, Yale New Haven Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06725030
- Sponsor's protocol ID
- CDC-00136
- Acronym
- PRECISE
- Status last verified
- Nov 2026
- First submitted
- 5 Dec 2024
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRECISE: A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
- ClinicalTrials.gov ID
- NCT06725030
- Acronym / sponsor ID
- PRECISE / CDC-00136
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 455 participants (estimated)
- Lead sponsor
- MMI (Medical Microinstruments, Inc.)Industry (pharma, biotech, devices)
- Study start
- 22 Sep 2025 (actual)
- Primary completion
- 1 Sep 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 9 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery.
The primary endpoints are:
- Effectiveness- Rate of intraoperative anastomosis patency at first attempt.
- Safety- Freedom from device-related adverse events.
Participants will receive treatment as standard of care and be asked to:
- Allow the researchers to access and use their information.
- If participants are undergoing a lymphedema procedure, they will be asked to undergo a questionnaire as part of the study.
- Participants will be asked to comply with the follow-up visits and complete all study procedures/questionnaires as outlined in the protocol.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Free Tissue Transfer Surgery | – | Device: Symani Surgical System |
| Lymphovenous Anastomosis Surgery | – | Device: Symani Surgical System |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patients selected for the PRECISE Study will be adults with a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free flap surgery of the breast or extremities and/or lymphovenous anastomosis surgery of the extremities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Symani Surgical SystemThe Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments. | Device | Free Tissue Transfer Surgery, Lymphovenous Anastomosis Surgery |
Primary outcome
Freedom from device-related adverse events from the start of the index procedure through 30-days post index procedure as adjudicated by a Clinical Events Committee
Time frame: From participants index procedure through 30-days post index procedure.
All adverse events will be evaluated from the start of the index procedure through 30-days post index procedure. Adverse events will be reviewed by a Clinical Events Committee (CEC) to determine probable or causal relationships with the device. All device-related serious adverse events will be summarized descriptively.
Intraoperative anastomosis patency at first attempt.
Time frame: The duration of the participants index procedure.
Intraoperative anastomosis patency will be measured for each robotic anastomosis per standard of care and will be evaluated after the first attempt of the anastomosis during the index procedure.
5 secondary outcomes
Intraoperative anastomosis patency prior to closure.
Time frame: The duration of participants index procedure.
Anastomosis suturing time (including robotic time and manual time).
Time frame: The duration of participants index procedure.
Number of robotic and manual stitches per anastomosis.
Time frame: The duration of participants index procedure.
Procedure time.
Time frame: The duration of participants index procedure.
Technical Success.
Time frame: The duration of participants index procedure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
Related trials for Open Surgery
Not yet recruitingPhase 2
Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II Randomized Control Trial
Oral and Maxillofacial Conditions
Not yet recruiting
Tailored Nutrition vs. Exercise Prehabilitation Before Colorectal Cancer Surgery
Colorectal Cancer, Colorectal Neoplasms
RecruitingPhase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Non Small Cell Lung Cancer
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingPhase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bohdan Pomahac, MD principal investigator
Yale New Haven Medical Center
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Open Surgery and Lymphedema, run by MMI (Medical Microinstruments, Inc.) at 8 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Operations (8336646276 ext. 5, clinical.ops@mmimicro.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Freedom from device-related adverse events from the start of the index procedure through 30-days post index procedure as adjudicated by a Clinical Events Committee (time frame: From participants index procedure through 30-days post index procedure.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.